Inhibition of RPS6K reveals context-dependent Akt activity in luminal breast cancer cells.
Aberrant signaling through insulin (Ins) and insulin-like growth factor I (IGF1) receptors contribute to the risk and advancement of many cancer types by activating cell survival cascades. Similarities between these pathways have thus far prevented the development of pharmacological interventions th...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-06-01
|
Series: | PLoS Computational Biology |
Online Access: | https://doi.org/10.1371/journal.pcbi.1009125 |
id |
doaj-5a50932ee04e4320af6e668981cb0eb3 |
---|---|
record_format |
Article |
spelling |
doaj-5a50932ee04e4320af6e668981cb0eb32021-07-24T04:32:00ZengPublic Library of Science (PLoS)PLoS Computational Biology1553-734X1553-73582021-06-01176e100912510.1371/journal.pcbi.1009125Inhibition of RPS6K reveals context-dependent Akt activity in luminal breast cancer cells.Cemal ErdemAdrian V LeeD Lansing TaylorTimothy R LezonAberrant signaling through insulin (Ins) and insulin-like growth factor I (IGF1) receptors contribute to the risk and advancement of many cancer types by activating cell survival cascades. Similarities between these pathways have thus far prevented the development of pharmacological interventions that specifically target either Ins or IGF1 signaling. To identify differences in early Ins and IGF1 signaling mechanisms, we developed a dual receptor (IGF1R & InsR) computational response model. The model suggested that ribosomal protein S6 kinase (RPS6K) plays a critical role in regulating MAPK and Akt activation levels in response to Ins and IGF1 stimulation. As predicted, perturbing RPS6K kinase activity led to an increased Akt activation with Ins stimulation compared to IGF1 stimulation. Being able to discern differential downstream signaling, we can explore improved anti-IGF1R cancer therapies by eliminating the emergence of compensation mechanisms without disrupting InsR signaling.https://doi.org/10.1371/journal.pcbi.1009125 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Cemal Erdem Adrian V Lee D Lansing Taylor Timothy R Lezon |
spellingShingle |
Cemal Erdem Adrian V Lee D Lansing Taylor Timothy R Lezon Inhibition of RPS6K reveals context-dependent Akt activity in luminal breast cancer cells. PLoS Computational Biology |
author_facet |
Cemal Erdem Adrian V Lee D Lansing Taylor Timothy R Lezon |
author_sort |
Cemal Erdem |
title |
Inhibition of RPS6K reveals context-dependent Akt activity in luminal breast cancer cells. |
title_short |
Inhibition of RPS6K reveals context-dependent Akt activity in luminal breast cancer cells. |
title_full |
Inhibition of RPS6K reveals context-dependent Akt activity in luminal breast cancer cells. |
title_fullStr |
Inhibition of RPS6K reveals context-dependent Akt activity in luminal breast cancer cells. |
title_full_unstemmed |
Inhibition of RPS6K reveals context-dependent Akt activity in luminal breast cancer cells. |
title_sort |
inhibition of rps6k reveals context-dependent akt activity in luminal breast cancer cells. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS Computational Biology |
issn |
1553-734X 1553-7358 |
publishDate |
2021-06-01 |
description |
Aberrant signaling through insulin (Ins) and insulin-like growth factor I (IGF1) receptors contribute to the risk and advancement of many cancer types by activating cell survival cascades. Similarities between these pathways have thus far prevented the development of pharmacological interventions that specifically target either Ins or IGF1 signaling. To identify differences in early Ins and IGF1 signaling mechanisms, we developed a dual receptor (IGF1R & InsR) computational response model. The model suggested that ribosomal protein S6 kinase (RPS6K) plays a critical role in regulating MAPK and Akt activation levels in response to Ins and IGF1 stimulation. As predicted, perturbing RPS6K kinase activity led to an increased Akt activation with Ins stimulation compared to IGF1 stimulation. Being able to discern differential downstream signaling, we can explore improved anti-IGF1R cancer therapies by eliminating the emergence of compensation mechanisms without disrupting InsR signaling. |
url |
https://doi.org/10.1371/journal.pcbi.1009125 |
work_keys_str_mv |
AT cemalerdem inhibitionofrps6krevealscontextdependentaktactivityinluminalbreastcancercells AT adrianvlee inhibitionofrps6krevealscontextdependentaktactivityinluminalbreastcancercells AT dlansingtaylor inhibitionofrps6krevealscontextdependentaktactivityinluminalbreastcancercells AT timothyrlezon inhibitionofrps6krevealscontextdependentaktactivityinluminalbreastcancercells |
_version_ |
1721284350278893568 |